EP4003317B1 - Ascorbat zur verhinderung von statininduzierter vaskulärer verkalkung - Google Patents

Ascorbat zur verhinderung von statininduzierter vaskulärer verkalkung Download PDF

Info

Publication number
EP4003317B1
EP4003317B1 EP20747478.4A EP20747478A EP4003317B1 EP 4003317 B1 EP4003317 B1 EP 4003317B1 EP 20747478 A EP20747478 A EP 20747478A EP 4003317 B1 EP4003317 B1 EP 4003317B1
Authority
EP
European Patent Office
Prior art keywords
vitamin
ascorbate
statin
mixture
ascorbic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
EP20747478.4A
Other languages
English (en)
French (fr)
Other versions
EP4003317A2 (de
Inventor
Vadim Ivanov
Aleksandra Niedzwiecki
Matthias Rath
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US16/524,383 external-priority patent/US11547693B2/en
Application filed by Individual filed Critical Individual
Priority to EP23198312.3A priority Critical patent/EP4279129A3/de
Publication of EP4003317A2 publication Critical patent/EP4003317A2/de
Application granted granted Critical
Publication of EP4003317B1 publication Critical patent/EP4003317B1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4415—Pyridoxine, i.e. Vitamin B6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A61K31/51—Thiamines, e.g. vitamin B1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7135—Compounds containing heavy metals
    • A61K31/714—Cobalamins, e.g. cyanocobalamin, i.e. vitamin B12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Definitions

  • the present invention relates to a mixture comprising L-ascorbic acid or ascorbate for use in preventing or mitigating the vascular calcification induced by statins.
  • Statins are also known as HMG-CoA reductase inhibitors and are a class of lipid-lowering compounds.
  • LDL Low-density lipoprotein
  • statins Upon treatment with statins, patients exhibit side effects including muscle pain, increased risk of diabetes mellitus, and abnormal blood levels of liver enzymes.
  • lovastatin leads to myopathy and asymptomatic, but marked and persistent increases in liver transaminases.
  • the transaminase increase produced by lovastatin and other HMG-CoA reductase inhibitors is a direct consequence of the inhibition of the mevalonate synthesis.
  • US 4,929,437 teaches the adjunct administration of an effective amount of HMG-CoA reductase inhibitor and an effective amount of coenzyme Q 10 in order to counter-act HMG-CoA reductase inhibitor-associated liver damage.
  • statins increase vascular calcifications, which are a recognized risk factor for heart disease (Ikegami Y, Inoue I, Inoue K, Shinoda Y3, lida S1, Goto S4, Nakano T5, Shimada A1, Noda M1.
  • the annual rate of coronary artery calcification with combination therapy with a PCSK9 inhibitor and a statin is lower than that with statin monotherapy. NPJ Aging Mech Dis 2018;4:7 ).
  • Vascular calcification is a relevant pathophysiological process that is associated with coronary atherosclerosis, and is a prognostic marker of cardiovascular morbidity and mortality.
  • Vascular smooth muscle cells have an extraordinary capacity to undergo osteoblastic phenotypical differentiation. Calcification of the intimal and/or medial vascular cell layer leads to differentiation of osteoblasts whether from a smooth muscle cell, a mesenchymal cell, or vascular pericyte, characterized, among others, by increased alkaline phosphatase activity, osteocalcin production and bone matrix secretion. Biochemical mechanisms associated with the conversion of SMC into osteoblastic cells have been elaborated, however the decisive mechanisms of what triggers and/or regulates this process have remained largely elusive.
  • plaque calcification is a dynamic process and related to the degree of vascular inflammation.
  • Several inflammatory factors produced during the different phases of atherosclerosis can induce the expression and activation of osteoblastic cells located within the arterial wall, which, in turn, promote deposition of calcium.
  • vascular smooth muscle cells vascular smooth muscle cells
  • calcifying vascular cells vascular smooth muscle cells
  • These cells are implicated in the synthesis/reabsorption of bone in atherosclerotic plaques, especially around calcification.
  • bone cell function in the vascular wall is, in some aspects, similar to that in bones.
  • in vitro studies provided evidence that regulation of bone synthesis in the vascular wall and in the skeleton are different.
  • osteoblasts of the skeleton and CVCs a population of vascular cells with osteoblastic characteristics
  • US 2004/0023919 A1 discloses a blood lipid ameliorant composition.
  • the pharmaceutical composition combines atorvastatin and an ascorbic acid derivative which can be sodium ascorbate, calcium ascorbate or ascorbic acid. Effects of co-administration of atorvastatin and ascorbic acid are shown in Table 8. Blood FFA levels were reduced when administering atorvastatin and ascorbic acid, see the last entry. Compositions containing atorvastatin and ascorbic acid are shown in Tables 1 to 4. In paragraph [0008] it is stated that co-administration of atorvastatin with a certain vitamin (ascorbic acid) reduces the total cholesterol levels in the blood.
  • US 2004/0014712 A1 discloses the combination of simvastatin and ascorbic acid. Blood lipid peroxide levels, blood FFA levels and CPK levels were reduced by the combination of simvastatin and ascorbic acid. Corresponding pharmaceutical compositions are listed in Tables 1 to 4. In paragraph [0006] it is stated that blood lipid levels are ameliorated by this combination.
  • US 2004/0009986 A1 discloses a combination of pravastatin and ascorbic acid derivatives. It is stated that blood triglyceride levels could be reduced by a combination of pravastatin with ascorbic acid (and additionally tocopherol or tocopherol and riboflavin butyrate). In paragraph [0007] it is stated that the drug composition reduces triglyceride levels in the blood.
  • WO 03/072013 A2 discloses a combination of a statin with ascorbic acid for the treatment of psoriasis.
  • the object underlying the present invention is to treat or prevent the vascular calcification induced in patients by administration of statins.
  • composition mixture comprising L-ascorbic acid or ascorbate, vitamin E, vitamin B1, vitamin B2, vitamin B3, vitamin B5, vitamin B6, vitamin B12, folic acid, biotin, L-carnitine and betaine is effective in treating or preventing the vascular calcification in a human system, especially when co-administered with statin.
  • Vitamin C is an essential nutrient for certain animals including humans. Clinical trials have shown a significant positive effect of vitamin C on endothelial function when taken at doses greater than 500 mg per day. Its possible influence on the treatment or prevention of cardiovascular disease has been discussed.
  • Vitamin C is a very powerful antioxidant and is essential for the formation of collagen and optimum extracellular matrix (ECM). It can prevent lipoprotein deposition and development of atherosclerosis by protecting the integrity and strength of the vascular wall.
  • vitamin C plays a decisive role in regulating the cellular and extracellular architecture and function inside the vascular wall.
  • the integrity and stability of the vascular wall would be provided, above all, by an optimum synthesis of collagen and other ECM molecules.
  • the need for compensatory mechanisms may arise to add compensatory stability to a structurally impaired vascular wall - including by means of calcification.
  • vitamin C also known as ascorbic acid or L-ascorbic acid
  • ascorbate can be employed, wherein the ascorbate, a salt of ascorbic acid with bases or acids stronger than ascorbic acid, is preferably selected from water-soluble or lipid-soluble ascorbates or mixtures thereof and is more preferably selected from the group consisting of calcium ascorbate, magnesium ascorbate, sodium ascorbate, ascorbyl phosphate, ascorbyl palmitate or mixtures thereof.
  • composition mixture 1 containing or consisting of vitamins C, E, B1, B2, B3, B5, B6, B12, folic acid, biotin, L-carnitine and betaine is (preferably) administered to patients that are treated with statins.
  • statins can also be described as HMG-CoA reductase inhibitors.
  • the statins inhibit the enzyme HMG-CoA reductase which is necessary to make cholesterol.
  • statins relate to a class of lipid-lowering medications that reduce illness and mortality in those who are at high risk of cardiovascular disease. All suitable statins can be employed in the context of the present invention.
  • the stain is selected from the group consisting of atorvastatin, cerivastatin, fluvastatin, lovastatin, mevastatin, pitavastatin, pravastatin, rosuvastatin, simvastatin, or mixtures thereof, or any other type or form of statin, or from a combination of the statin with niacin.
  • the composition mixture 1 can be administered together with one or more additional micronutrients beside L-ascorbic acid or ascorbate.
  • a pharmaceutical composition comprising composition mixture 1, and one or more additional micronutrients can be provided for this purpose.
  • the one or more additional micronutrients are administered together with composition mixture 1 and with statin.
  • the one or more micronutrients are preferably selected from trace minerals, vitamins different from composition mixture comprising L-ascorbic acid or ascorbate, vitamin E, vitamin B1, vitamin B2, vitamin B3, vitamin B5, vitamin B6, vitamin B12, folic acid, biotin, L-carnitine and betaine, and mixtures thereof. Trace minerals are only required in small amounts (traces) by humans.
  • Trace minerals are preferably selected from boron, cobalt (preferably as a component of vitamin B12), chromium, copper, iodine, iron, manganese, molybdenum, selenium, zinc, and mixtures thereof.
  • Vitamins different from vitamin C are preferably selected from vitamin B complex, vitamin B1 (thiamin), vitamin B2 (riboflavin), vitamin B3 (niacin), vitamin B5 (pantothenic acid), vitamin B6 group including pyridoxine, pyridoxal-5-phosphate, and pyridoxamine, vitamin B7 (biotin), vitamin B9 (folate or folic acid), vitamin B12 (cobalamin), comprised in the composition mixture, choline, vitamin A (e.g.
  • retinol or provitamin A carotenoids include vitamin D, including ergocalciferol and cholecalciferol, vitamin E (tocopherols and tocotrienols), vitamin K including vitamin K1 (phylloquinone) and vitamin K2 (menaquinone), carotenoids, including alpha carotene, beta carotene, cryptoxanthin, lutein, lycopene and Zeaxanthin.
  • Micronutrients comprised in the composition mixture include folic acid, biotin, L-carnitine and betaine.
  • Amino acids and their derivatives include betaine and L-carnitine.
  • Further micronutrients comprise vitamins B6 and B12, folic acid and betaine.
  • a preferred combination of micronutrients is contained in composition mixture 1 as outlined below.
  • the daily dosage amount can be from the lowest to the highest commercially available or clinically applicable dose.
  • the dosage amount is preferably in the range of from 5 to 100 mg, preferred 10 to 80 mg, more preferably 10 to 40 mg, most preferably 10 to 20 mg.
  • the amount of L-ascorbic acid or ascorbate administered to a patient receiving statin treatment is preferably 10 mg to 100 g, more preferably 100 mg to 10 g, most preferably 200 mg to 5 g daily dosage.
  • composition mixture 1 as described below simultaneously with the statin, for example in a tablet containing both, composition mixture 1 as described below, and statin. Furthermore, it is possible to administer composition mixture 1 as described below and statin in separate pharmaceutical compositions, but concomitantly.
  • concomitantly means that the administration of both active ingredients takes place within a time range of from 0 to 5 hours, preferably 0 to 3 hours, more preferably 0 to 1 hours, based on one administration per day.
  • statins and L-ascorbic acid or ascorbate are well established for an individual and separate administration to patients in need thereof, the known pharmaceutical or nutritional compositions or mixture 1 as described below can be employed according to the present invention while ensuring the concomitant use of both active ingredients, the mixture 1 and the statin.
  • a micronutrient composition that contains ascorbate and can advantageously be employed in combination with statins is mixture 1.
  • Mixture 1 contains vitamins, L-carnitine and betaine, and specifically contains or consists of vitamins C, E, B1, B2, B3, B5, B6, B12, folic acid, biotin, L-carnitine and betaine, and can be employed for daily nutritional supplementation.
  • three tablets are taken for a day (one tablet three times a day at meal times with plenty of liquid (water, juice, tea)).
  • Composition mixture 1 contains each nutrient in the range for one to three tablets as follows:
  • Composition mixture 1 contains selected micronutrients in a synergistic combination. This reconstructive formula can be combined with other basic formulas, e.g. Vitacor Plus TM .
  • a tablet contains typically the following ingredients: vitamin C, cellulose filler, vitamin B3, L-carnitine tartrate 5.26%, release agent stearic acid, betaine hydrochloride 3.24%, vitamin E, vitamin B5, croscarmellose sodium, glazing agent calcium carbonate, maltodextrin, release agent silicon dioxide, glazing agent shellac, vitamin B1, vitamin B6, biotin, coloring agent riboflavin (vitamin B2), coconut oil extract, folic acid, vitamin B2, lemon oil, vitamin B12, natural lemon flavor.
  • Vitamins B6 and B12, folic acid and betaine are important factors for assisting the normal homocysteine metabolism. Therefore, optimal supply of these micronutrients is essential for maintaining normal homocysteine levels.
  • composition mixture 1 supports cellular metabolism in many ways simultaneously, e.g.:
  • the recommended daily dose can be as indicated above, or can be 10 to 300%, preferably 20 to 200%, more preferably 50 to 150% thereof.
  • the ascorbate employed is preferably obtained from identical amounts of calcium ascorbate and magnesium ascorbate.
  • composition mixture 1 and/or the statin can be combined with coenzyme Q 10 in a combined pharmaceutical composition or in separate pharmaceutical compositions, as outlined in US 4,929,437 .
  • composition mixture 1 is for use in treating or preventing the vascular calcification, specifically the vascular calcification induced in patients by administration of statins.
  • treating in this context means “mitigating” or “reversing”.
  • vascular smooth muscle cells SMC
  • AoSMC human aortic smooth muscle cells
  • the present invention is specifically based on the positive effect of vitamin C on vascular SMC, human dermal fibroblasts (DF) as well as immortalized human fetal osteoblasts (FOB).
  • DF human dermal fibroblasts
  • FOB immortalized human fetal osteoblasts
  • the process of vascular calcification requires a phenotypic transformation of vascular smooth muscle cells (VSMC) into osteogenic cells.
  • the concomitant administration of at least one statin and composition mixture 1 to a patient is helpful for treating or preventing cardiovascular disease, for example coronary artery disease, cerebrovascular disease or peripheral vascular disease.
  • cardiovascular disease for example coronary artery disease, cerebrovascular disease or peripheral vascular disease.
  • statin-induced calcification could be beneficial or that there could be a beneficial macro-calcification, as opposed to detrimental micro-calcification.
  • Mixture 1 nutritional supplement was dissolved according to US Pharmacopea standard procedure (USP 2040 Disintegration and Dissolution of Dietary Supplements) as follows: Three recommended daily doses (nine tablets) were crushed and suspended in 900 ml 0.1 N HCl. Following one hour incubation in water bath incubator at 37°C on an orbital shaker at 75 rpm, the supplement suspension was filtered through a 0.2 mcm sterile filter, and 1 ml aliquots were frozen and stored at 20°C until use. The resulted mixture 1 solution contained 19 mM ascorbic acid according to the manufacturer's specification.
  • DF normal human dermal fibroblasts
  • hFOB immortalized human fetal osteoblasts
  • ATCC Manassas, VA, USA
  • Human aortic smooth muscle cells AoSMC
  • ATCC DMEM medium
  • FBS fetal bovine serum
  • pro-osteogenic medium defines as 5% FBS/DMEM fortified with 5 mM beta-glycerophosphate with or without 25 mcM forskolin. All cell cultures were maintained at 37°C and 5% CO 2 atmosphere. Cell viability was monitored with MTT assay.
  • AoSMC were plated in 96 well plates and grown to confluent layer. Cells were incubated with ascorbic acid in growth medium for three days. Cells were washed with phosphate buffered saline (PBS) and supplemented with 50 mcl/well 25 mcg/ml 4-MUP (fluorescent ALP substrate, Sigma) in alkaline buffer (Sigma)/1 % Triton X100 for 1h at room temperature. Fluorescence was measured at 360/450 nm.
  • AoSMC were seeded on fibronectin covered plastic plates at density 25,000 per square cm and grown to confluence for 5-7 days. Ascorbic acid or mixture 1 was added to cells at indicated concentrations for 72 hours in DMEM supplemented with 2% FBS and cell-produced extracellular matrix was exposed by sequential treatment with 0.5% Triton X100 and 20 mM ammonium sulfate in phosphate buffered saline (PBS, Life Technologies) for 3 min each at room temperature as described in Ivanov V, Ivanova S, Kalinovsky T, Niedzwiecki A, Rath M. Plant-derived micronutrients suppress monocyte adhesion to cultured human aortic endothelial cell layer by modulating its extracellular matrix composition.
  • PBS phosphate buffered saline
  • DF and hFOB cells were seeded in separate 96 well plastic plates at density 25,000 per square cm and grown to confluence for 5-7 days. Tested compounds were added to cells at indicated concentrations for 72 hours in DMEM supplemented with 2% FBS. Cell layers were washed three times with PBS and fixed with 3% formaldehyde in PBS at 4°C for one hour. Fixed cell layers were washed four times with PBS and treated with 1% BSA/PBS for one hour at RT.
  • Immunoassay for osteogenic markers was done by sequential incubation with primary monoclonal antibodies (R&D Systems) in 1% BSA/PBS for 2 hours followed by 1 hour incubation with secondary goat anti-mouse IgG antibodies labeled with horse radish peroxidase (HRP). Retained peroxidase activity was measured after the last washing cycle (three times with 0.1% BSA/PBS) using TMB peroxidase substrate reagent (Rockland). Optical density was read with plate reader (Molecular Devices) at 450 nm and expressed as percentage of control cell samples incubated in unsupplemented 2%FBS/DMEM. To ensure a direct comparison of osteogenic markers expression on different cell types all pcell covered plates were treated identical and simultaneously during immunoassay.
  • Results in figures are means ⁇ standard deviation SD from three or more repetitions from the most representative of at least two independent experiments. Differences between samples were estimated with a two-tailed Student's t-test using Excel software (Microsoft) and accepted as significant at p levels less than 0.05.
  • Figure 1 shows the effects of treatment with ascorbic acid on calcification of extracellular matrix in cultured human aortic smooth muscle cells.
  • Figure 2A shows the effects of Simvastatin on Ca accumulation in AoSMC culture without forskolin.
  • Figure 2B shows the effects of mevastatin on Ca accumulation in AoSMC culture with 25 mcM forskolin.
  • Figure 3A shows the effects of 200 mcM ascorbate on osteoblast markers expression in human aortic SMC incubated for 4 weeks in osteogenic medium supplemented with 5 mM beta-glycerophosphate and 25 mcM forskolin.
  • Figure 3B shows effects of 200 mcM ascorbate on osteoblast markers expression in human dermal fibroblasts incubated for 4 weeks in osteogenic medium supplemented with 5 mM beta-glycerophosphate and 25 mcM forskolin.
  • Figure 4A shows effects of 1 mcM statins and Mixture 1 (at 100 mcM ascorbate) on alkaline phosphatase activity in AoSMC supplemented in plain 5% FBS/DMEM for four days. 90 min incubation with MSU substrate.
  • Figure 4B shows the effects of 1 mcM statins and Mixture 1 (and 100 mcM ascorbate) on alkaline phosphatase activity in AoSMC supplemented in 5 mM b-GP and 25 mcM forskolin for four days. 95 min incubation with MSU substrate.
  • Figure 5A shows the effects of 1 mcM statins and 300 mcM ascorbate on alkaline phosphatase activity in AoSMC supplemented in plain 5% FBS/DMEM for five days.
  • Figure 5B shows the effects of 1 mcM statins and 300 mcM ascorbate on alkaline phosphatase activity in AoSMC supplemented in 5% FBS/DMEM/5mM b-GP, 25 mcM forskolin for five days.
  • AoSMC Cellular calcification process was investigated in human AoSMC cultured in a regular cell growth medium (5% FBS/DMEM) in the absence and presence of various amounts of ascorbic acid.
  • the calcification process of AoSMC was evaluated by the activity of cellular alkaline phosphatase and calcium accumulation in the cell-produced extracellular matrix ( Figure 1 ).
  • ascorbic acid tested up to 300 mcM concentrations can reduce calcium accumulation in ECM produced by AoSMC.
  • This effect was accompanied by the blockage of SMC osteogenic transformation as indicated by changes in specific metabolic parameters, such as reduction in cellular alkaline phosphatase activity, and cellular expression of osteoblast marker proteins.
  • a high level of serum alkaline phosphatase (ALP) is associated with an increased risk of mortality and myocardial infarction.
  • ALP hydrolyses inorganic pyrophosphate, which is a strong inhibitor of calcium phosphate deposition. Table 1.
  • osteocalcin Under physiological conditions (cells incubated in regular cell culture medium) expression of osteocalcin, osteoadherin and SOST/sclerostin were the highest in hFOS cultures and the lowest in hAoSMC cultures. Expression of these markers were intermediate in hDF cultures. Under physiological conditions (cells incubated in regular cell culture medium) expression of DMP-1 was the highest in hDF cultures and the lowest in hAoSMC cultures. Expression of DMP-1 was intermediate in hFOS cultures. Cell supplementation with pro-osteogenic medium as compared to regular medium caused stimulation of all tested osteomarkers in AoSMC cultures. In contrast, pro-osteogenic medium supplementation caused an inhibition of all tested osteogenic markers in hDF and hFOS cultures.
  • mixture 1 micronutrient combination containing ascorbate
  • ascorbate individually under standard (5% FBS/DMEM)
  • pro-calcification conditions 5% FBS/DMEM supplemented with 5 mM beta-glycerophosphate (b-GP) and 25 mcM forskolin - Figure 4B ).
  • mixture 1 and/or vitamin C plays a decisive role in regulating the cellular and extracellular architecture and function inside the vascular wall.
  • the integrity and stability of the vascular wall would be provided, above all, by an optimum synthesis of collagen and other ECM molecules.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Claims (17)

  1. Ein Zusammensetzungsgemisch, umfassend L-Ascorbinsäure oder Ascorbat, Vitamin E, Vitamin B1, Vitamin B2, Vitamin B3, Vitamin B5, Vitamin B6, Vitamin B12, Folsäure, Biotin, L-Carnitin und Betain zur Verwendung in der Behandlung oder Vorbeugung vaskulärer Verkalkungen, die in Patienten durch Verabreichung von Statinen induziert sind.
  2. Das Zusammensetzungsgemisch nach Anspruch 1 zur Verwendung in der Behandlung von Patienten, die gleichzeitig eine Statinbehandlung erfahren.
  3. Das Zusammensetzungsgemisch zur Verwendung nach Anspruch 1 oder 2, wobei das Zusammensetzungsgemisch die folgenden Mengen enthält:
    L-Ascorbinsäure oder Ascorbat: 300 mg bis 1000.2 mg
    Vitamin E: 27,5 mg bis 82,5 mg,
    Vitamin B1: 3.3 mg bis 9.9 mg,
    Vitamin B2: 3,3 mg bis 9,9 mg,
    Vitamin B3: 115 mg bis 350,1 mg,
    Vitamin B5: 16,7 mg bis 50,1 mg,
    Vitamin B6: 3,3 mg bis 9,9 mg,
    Vitamin B12: 10 µg bis 30 µg,
    Folsäure: 133,3 µg bis 399,9 µg,
    Biotin: 33,3 µg bis 99,9 µg,
    L-Carnitin: 33,3 mg bis 99,9 mg,
    Betain: 23,3 mg bis 69,9 mg.
  4. Das Zusammensetzungsgemisch zur Verwendung nach einem der Ansprüche 1 bis 3, wobei das Ascorbat ausgewählt ist aus wasserlöslichen oder lipidlöslichen Ascorbaten oder deren Gemischen, vorzugsweise aus Calciumascorbat, Magnesiumascorbat, Natriumascorbat, Ascorbylphosphat, Ascorbylpalmitat oder Gemischen davon.
  5. Eine pharmazeutische Zusammensetzung, enthaltend mindestens ein Statin und L-Ascorbinsäure oder Ascorbat, Vitamin E, Vitamin B1, Vitamin B2, Vitamin B3, Vitamin B5, Vitamin B6, Vitamin B12, Folsäure, Biotin, L-Carnitin und Betain in einer Dosierungsform, die die gleichzeitige Verabreichung des mindestens eines Statins mit L-Ascorbinsäure oder Ascorbat und Vitamin E, Vitamin B1, Vitamin B2, Vitamin B3, Vitamin B5, Vitamin B6, Vitamin B12, Folsäure, Biotin, L-Carnitin und Betain an einen Patienten erlaubt.
  6. Die pharmazeutische Zusammensetzung nach Anspruch 5 oder 6, wobei das mindestens eine Statin und L-Ascorbinsäure oder Ascorbat, Vitamin E, Vitamin B1, Vitamin B2, Vitamin B3, Vitamin B5, Vitamin B6, Vitamin B12, Folsäure, Biotin, L-Carnitin und Betain als physikalisches Gemisch oder als separate pharmazeutische Zusammensetzungen für die gleichzeitige Verabreichung an einen Patienten vorliegen.
  7. Die pharmazeutische Zusammensetzung nach Anspruch 5 zur Verwendung in der Behandlung oder Vorbeugung von Herz-Kreislauf-Erkrankungen.
  8. Die pharmazeutische Zusammensetzung zur Verwendung nach Anspruch 7, wobei die Herz-Kreislauf-Erkrankungen koronare Herzkrankheit, cerebrovaskuläre Krankheit oder periphere arteriosklerotische Gefäßerkrankung sind.
  9. Die pharmazeutische Zusammensetzung nach einem der Ansprüche 5 bis 8, wobei das Statin ausgewählt ist aus der Gruppe bestehend aus Atorvastatin, Cerivastatin, Fluvastatin, Lovastatin, Mevastatin, Pitavastatin, Pravastatin, Rosuvastatin, Simvastatin oder Gemischen davon.
  10. Die pharmazeutische Zusammensetzung nach einem der Ansprüche 5 bis 9, wobei das Ascorbat ausgewählt ist aus wasserlöslichen oder lipidlöslichen Ascorbaten oder Gemischen davon, vorzugsweise aus Calciumascorbat, Magnesiumascorbat, Natriumascorbat, Ascorbylphosphat, Ascorbylpalmitat oder Gemischen davon.
  11. Die pharmazeutische Zusammensetzung nach einem der Ansprüche 5 bis 10, zusätzlich enthaltend Coenzym Q10 in einer Dosierform, die die gleichzeitige Verabreichung mit dem mindestens einen Statin, L-Ascorbinsäure oder Ascorbat und Coenzym Q10 an einen Patienten erlaubt.
  12. Die pharmazeutische Zusammensetzung nach einem der Ansprüche 5 bis 11, umfassend eine tägliche Dosismenge an L-Ascorbinsäure oder Ascorbat von 10 mg bis 100 g, und von mindestens einem Statin von 5 mg bis 100 mg.
  13. Die pharmazeutische Zusammensetzung nach einem der Ansprüche 5 bis 12, enthaltend die folgenden Mengen
    Vitamin E: 27,5 mg bis 82,5 mg,
    Vitamin B1: 3.3 mg bis 9.9 mg,
    Vitamin B2: 3,3 mg bis 9,9 mg,
    Vitamin B3: 115 mg bis 350,1 mg,
    Vitamin B5: 16,7 mg bis 50,1 mg,
    Vitamin B6: 3,3 mg bis 9,9 mg,
    Vitamin B12: 10 µg bis 30 µg,
    Folsäure: 133,3 µg bis 399,9 µg,
    Biotin: 33,3 µg bis 99,9 µg,
    L-Carnitin: 33,3 mg bis 99,9 mg,
    Betain: 23,3 mg bis 69,9 mg
    in der pharmazeutischen Zusammensetzung.
  14. Die pharmazeutische Zusammensetzung nach Anspruch 13, ferner enthaltend Niacin, vorzugsweise in einem Gemisch mit dem Statin.
  15. Ein Zusammensetzungsgemisch 1 umfassend oder bestehend aus Vitamin C, Vitamin E, Vitamin B1, Vitamin B2, Vitamin B3, Vitamin B5, Vitamin B6, Vitamin B12, Folsäure, Biotin, L-Carnitin und Betain enthaltend oder bestehend aus folgenden Mengen:
    Vitamin C: 300 mg bis 1000.2 mg
    Vitamin E: 27,5 mg bis 82,5 mg,
    Vitamin B1: 3.3 mg bis 9.9 mg,
    Vitamin B2: 3,3 mg bis 9,9 mg,
    Vitamin B3: 115 mg bis 350,1 mg,
    Vitamin B5: 16,7 mg bis 50,1 mg,
    Vitamin B6: 3,3 mg bis 9,9 mg,
    Vitamin B12: 10 µg bis 30 µg,
    Folsäure: 133,3 µg bis 399,9 µg,
    Biotin: 33,3 µg bis 99,9 µg,
    L-Carnitin: 33,3 mg bis 99,9 mg,
    Betain: 23,3 mg bis 69,9 mg
    im Zusammensetzungsgemisch.
  16. Das Zusammensetzungsgemisch 1 nach Anspruch 15, wobei das Vitamin C in Ascorbatform vorliegt, wobei das Ascorbat vorzugsweise ausgewählt ist aus wasserlöslichen oder lipidlöslichen Ascorbaten oder Gemischen davon, stärker bevorzugt, wobei das Ascorbat ausgewählt ist aus Calciumascorbat, Magnesiumascorbat, Natriumascorbat, Ascorbylphosphat, Ascorbylpalmitat oder Gemischen davon.
  17. Das Zusammensetzungsgemisch 1 nach einem der Ansprüche 15 oder 16, zusätzlich umfassend ein Coenzym Q10.
EP20747478.4A 2019-07-29 2020-07-27 Ascorbat zur verhinderung von statininduzierter vaskulärer verkalkung Active EP4003317B1 (de)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP23198312.3A EP4279129A3 (de) 2019-07-29 2020-07-27 Ascorbat zur vorbeugung von statininduzierter gefässverkalkung

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US16/524,383 US11547693B2 (en) 2019-07-29 2019-07-29 Ascorbate in the prevention of statin induced vascular calcification
EP19190436 2019-08-07
US201916562313A 2019-09-05 2019-09-05
PCT/IB2020/057063 WO2021019421A2 (en) 2019-07-29 2020-07-27 Ascorbate in the prevention of statin induced vascular calcification

Related Child Applications (1)

Application Number Title Priority Date Filing Date
EP23198312.3A Division EP4279129A3 (de) 2019-07-29 2020-07-27 Ascorbat zur vorbeugung von statininduzierter gefässverkalkung

Publications (2)

Publication Number Publication Date
EP4003317A2 EP4003317A2 (de) 2022-06-01
EP4003317B1 true EP4003317B1 (de) 2023-09-20

Family

ID=71846427

Family Applications (2)

Application Number Title Priority Date Filing Date
EP23198312.3A Pending EP4279129A3 (de) 2019-07-29 2020-07-27 Ascorbat zur vorbeugung von statininduzierter gefässverkalkung
EP20747478.4A Active EP4003317B1 (de) 2019-07-29 2020-07-27 Ascorbat zur verhinderung von statininduzierter vaskulärer verkalkung

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EP23198312.3A Pending EP4279129A3 (de) 2019-07-29 2020-07-27 Ascorbat zur vorbeugung von statininduzierter gefässverkalkung

Country Status (9)

Country Link
EP (2) EP4279129A3 (de)
JP (1) JP2022543049A (de)
KR (1) KR20220041879A (de)
AU (1) AU2020322231A1 (de)
BR (1) BR112022001422A2 (de)
CA (1) CA3145041A1 (de)
ES (1) ES2965346T3 (de)
PL (1) PL4003317T3 (de)
WO (1) WO2021019421A2 (de)

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0347864A3 (de) * 1988-06-24 1992-04-01 Andries Johannes Cornelus Strydom Antiatherosklerose-Mittel
US4929437A (en) 1989-02-02 1990-05-29 Merck & Co., Inc. Coenzyme Q10 with HMG-CoA reductase inhibitors
US7037934B2 (en) * 2000-12-14 2006-05-02 Sankyo Company, Limited Blood lipid ameliorant composition
AU2002221131A1 (en) * 2000-12-14 2002-06-24 Sankyo Company Limited Blood lipid ameliorant composition
EP1214893A1 (de) * 2000-12-16 2002-06-19 Aventis Pharma Deutschland GmbH Zusammensetzungen zur Verbesserung der Gesundheit
TWI284529B (en) * 2000-12-18 2007-08-01 Sankyo Co A composition for lowering triglyceride
ES2192988B1 (es) * 2002-02-28 2005-02-16 Jose Manuel Quesada Gomez Nuevas aplicaciones de las estatinas en dermatologia y las correspondientes formulaciones farmaceuticas.
US7034012B2 (en) * 2002-11-01 2006-04-25 Matthias Rath Composition and method for prevention and treatment of arrhythmias
JP4880685B2 (ja) * 2005-07-22 2012-02-22 ザ プロクター アンド ギャンブル カンパニー 薬物による不整脈の発生を低減するための組成物
US20070265211A1 (en) * 2006-05-12 2007-11-15 Matthias Rath Novel composition and method effective in inhibiting the atherogenic process
US8911798B2 (en) * 2007-09-17 2014-12-16 Ajay Gupta Multivitamin and mineral compositions for individuals having renal disease
US20100021573A1 (en) * 2008-07-22 2010-01-28 Michael J Gonzalez Compositions and methods for the prevention of cardiovascular disease
JP6053945B2 (ja) * 2012-11-23 2016-12-27 ペキン ユニバーシティ サード ホスピタルＰｅｋｉｎｇ Ｕｎｉｖｅｒｓｉｔｙ Ｔｈｉｒｄ Ｈｏｓｐｉｔａｌ 肥満症、糖尿病、高血圧症及び高脂血症を治療するための局所薬としてのスタチン化合物の使用
US20170348280A1 (en) * 2016-06-06 2017-12-07 Matthias W Rath Counteracting the inhibition of collagen synthesis by select calcium and sodium channel blockers using ascorbic acid and ascorbyl palmitate

Also Published As

Publication number Publication date
PL4003317T3 (pl) 2024-03-04
JP2022543049A (ja) 2022-10-07
CA3145041A1 (en) 2021-02-04
EP4279129A3 (de) 2024-05-29
EP4279129A2 (de) 2023-11-22
WO2021019421A2 (en) 2021-02-04
WO2021019421A3 (en) 2021-03-25
BR112022001422A2 (pt) 2022-03-22
AU2020322231A1 (en) 2022-02-24
ES2965346T3 (es) 2024-04-12
EP4003317A2 (de) 2022-06-01
KR20220041879A (ko) 2022-04-01

Similar Documents

Publication Publication Date Title
US11344575B2 (en) Vascular calcification prevention and treatment
CA2794424C (en) Multi-vitamin and mineral nutritional supplements
US20250025522A1 (en) Composition
US20130165396A1 (en) Apple Skin Extracts for Treating Cardiovascular Disease
US20070141171A1 (en) Novel composition and method for the treatment of hypertension
US10736872B1 (en) Pharmaceutical mixture to treat statin induced vascular calcification
EP4003317B1 (de) Ascorbat zur verhinderung von statininduzierter vaskulärer verkalkung
Li et al. The role of fat-soluble vitamins on bone metabolism and osteoporosis: a literature review
EP1036510B1 (de) Vitamin Formulierung für kardiovaskuläre Gesundheit
RU2830123C2 (ru) Аскорбат в профилактике вызванной статинами кальцификации сосудов
US11911363B2 (en) Ascorbate in the prevention of statin induced vascular calcification
US20220175799A1 (en) Compositions having the ability to promote healthy cholesterol levels
Davidson et al. Efficacy of over-the-counter nutritional supplements
US20190111064A1 (en) Statin + vitamin d combination drug and method of use
Ara et al. Potential health benefits of vitamin C: an update
US20070265211A1 (en) Novel composition and method effective in inhibiting the atherogenic process
Wahlqvist et al. Micronutrients: vitamins
Menon et al. Multivitamins: use or misuse?
Murali et al. NUTRACEUTICALS FOR THE MANAGEMENT OF OSTEOPOROSIS: A REVIEW.
Batra Vitamins B6, B9, and B12
Nykamp et al. Vitamins: the wise choice for women with cardiovascular disease
US20020128320A1 (en) Method of administering calcium citrate
Landa Effect of blueberry polyphenols on osteoclast differentiation and activity
Tatti et al. Efficacy of plant sterols in novel matrices on blood lipid profiles: medium-chain triglycérides and low-fat products consumed with or without a meal.
Juturu 17 Tocopherol and Tocotrienols

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: UNKNOWN

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20220224

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: GRANT OF PATENT IS INTENDED

INTG Intention to grant announced

Effective date: 20230331

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE PATENT HAS BEEN GRANTED

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602020017997

Country of ref document: DE

P01 Opt-out of the competence of the unified patent court (upc) registered

Effective date: 20231013

REG Reference to a national code

Ref country code: NL

Ref legal event code: FP

REG Reference to a national code

Ref country code: GR

Ref legal event code: EP

Ref document number: 20230402106

Country of ref document: GR

Effective date: 20231211

REG Reference to a national code

Ref country code: LT

Ref legal event code: MG9D

REG Reference to a national code

Ref country code: DE

Ref legal event code: R082

Ref document number: 602020017997

Country of ref document: DE

Representative=s name: ALTMANN STOESSEL DICK PATENTANWAELTE PARTG MBB, DE

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20230920

Ref country code: RS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20230920

Ref country code: NO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20231220

Ref country code: LV

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20230920

Ref country code: LT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20230920

Ref country code: HR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20230920

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20230920

REG Reference to a national code

Ref country code: AT

Ref legal event code: MK05

Ref document number: 1612879

Country of ref document: AT

Kind code of ref document: T

Effective date: 20230920

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20240120

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2965346

Country of ref document: ES

Kind code of ref document: T3

Effective date: 20240412

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20230920

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SM

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20230920

Ref country code: RO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20230920

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20240120

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20230920

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20230920

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20230920

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20240122

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20230920

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 602020017997

Country of ref document: DE

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20230920

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20230920

26N No opposition filed

Effective date: 20240621

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20230920

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20230920

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20230920

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20230920

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20230920

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20240727

GBPC Gb: european patent ceased through non-payment of renewal fee

Effective date: 20240727

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20240727

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20240731

Ref country code: GR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20250205

Ref country code: BE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20240731

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GB

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20240727

REG Reference to a national code

Ref country code: BE

Ref legal event code: MM

Effective date: 20240731

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20240727

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20240727

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: NL

Payment date: 20250721

Year of fee payment: 6

REG Reference to a national code

Ref country code: ES

Ref legal event code: FD2A

Effective date: 20250827

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: ES

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20240728

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 20250722

Year of fee payment: 6

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 20250725

Year of fee payment: 6

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PL

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20240727

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO

Effective date: 20200727

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: HU

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO

Effective date: 20200727